Protox to Present Benign Prostatic Hyperplasia Data at Canadian Urology Conference
Protox Therapeutics Inc. , a leader in the development of receptor targeted fusion proteins, announced that data from their open label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia, will be presented this afternoon at the 64th Annual Meeting of the Canadian Urological Association. The 2009 CUA Meeting is the country's largest gathering of urology professionals taking place at the Westin Harbour Castle Hotel in Toronto, Ontario. [more...]
|
|
|
